In fact, it has been noted that around 30% of patients with IBD show a primary non-response to anti-TNF therapies and, over time, around 50% of patients discontinue the treatment due to the loss of secondary response or even the appearance of adverse effects [9,10,11]. Here, TNF is linked to inflammatory bowel disease.